Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Non Operating Income (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Non Operating Income for 15 consecutive years, with -$449000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 15.76% year-over-year to -$449000.0, compared with a TTM value of -$1.9 million through Sep 2025, up 32.13%, and an annual FY2024 reading of -$2.6 million, up 19.4% over the prior year.
  • Non Operating Income was -$449000.0 for Q3 2025 at Fennec Pharmaceuticals, down from -$420000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $190000.0 in Q1 2021 and bottomed at -$906000.0 in Q1 2024.
  • Average Non Operating Income over 5 years is -$493937.5, with a median of -$523500.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 2211.11% in 2021, while the deepest fall reached 723.08% in 2021.
  • Year by year, Non Operating Income stood at -$1000.0 in 2021, then plummeted by 72100.0% to -$722000.0 in 2022, then decreased by 19.67% to -$864000.0 in 2023, then increased by 20.6% to -$686000.0 in 2024, then soared by 34.55% to -$449000.0 in 2025.
  • Business Quant data shows Non Operating Income for FENC at -$449000.0 in Q3 2025, -$420000.0 in Q2 2025, and -$357000.0 in Q1 2025.